Transforming the Prevention, Diagnosis, and Treatment of Kidney Disease

Transforming the Prevention and Diagnosis of Kidney Disease

-KIT Bio, a Nephrosant Company


“For too long we’ve resigned to accept the status quo for the treatment of kidney disease.”


-Bruce Greenstein, U.S. Department of Health & Human Services (HHS) Chief Technology Officer

Chronic Kidney Disease, or CKD, is a global public health crisis. 1 out of 9 of people worldwide have CKD. In the United States, that number is 1 out of 6.

In the U.S., $30 billion is spent by Medicare on CKD and End-Stage Renal Disease.


While early detection saves money and increases therapeutic options, diagnostics to detect early kidney injury did not exist.

Until now.

The KIT Assay and Score provides a quantitative measure of kidney injury, detecting injury in its earliest stages and providing a risk score that enables clinicians to intervene.